Web3
Alumis (ALMS) Stock in Freefall as Lupus Drug Fails Its Biggest Test
CoinCentral·September 1, 2026·1 min read
Alumis stock fell roughly 56% after its Phase 2b LUMUS trial of envudeucitinib failed to meet primary and secondary endpoints in overall lupus patients. The study of 408 patients missed the primary endpoint at Week 48. A subgroup showed strong responses, but not enough for efficacy.
Read at CoinCentralDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.